Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus CHILDREN S MOTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus CHILDREN S MOTRIN.
ANSAID vs CHILDREN'S MOTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
2-4 hours in children; prolonged in neonates and hepatic impairment.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Category C
Category C
NSAID
NSAID